Cargando…

Early Normalization of Free Light Chains Predicts Better Outcomes in Patients with Multiple Myeloma

Background: The half-life of free light chain is short and can be used as an early marker for tumor response in patients with multiple myeloma [MM]. This prospective study is aimed at evaluating whether early light chain response can predict response to treatment in patients with MM. Materials and M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benson, Rony, Nair, Sreejith G, Narayanan, Geetha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876429/ https://www.ncbi.nlm.nih.gov/pubmed/33603983 http://dx.doi.org/10.18502/ijhoscr.v14i4.4475

Ejemplares similares

Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome
por: Anoop, T.M., et al.
Publicado: (2022)

Multiple myeloma: Detection of free monoclonal light chains by modified immunofixation electrophoresis with antisera against free light chains
por: Wilhite, Dorian, et al.
Publicado: (2021)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma
por: Willrich, Maria Alice V., et al.
Publicado: (2022)

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma
por: Claveau, Jean-Sébastien, et al.
Publicado: (2022)

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients
por: García de Veas Silva, José Luis, et al.
Publicado: (2016)

Light chain myeloma and detection of free light chains in serum and urine of dogs and cats
por: Harris, Robert Adam, et al.
Publicado: (2021)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity
por: Berek, Klaus, et al.
Publicado: (2021)

Light-Chain Multiple Myeloma: A Diagnostic Challenge
por: Silva, Cristina, et al.
Publicado: (2021)

Crystalline light chain cast nephropathy in multiple myeloma
por: Lin, Zi-Shan, et al.
Publicado: (2021)

Multiple myeloma with acute light chain cast nephropathy
por: Leung, Nelson, et al.
Publicado: (2023)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

Utility of Serum Free Light Chain Measurements in Multiple Myeloma Patients Not Achieving Complete Response to Therapy
por: Moustafa, Muhamad Alhaj, et al.
Publicado: (2015)

Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients
por: Pendón-Ruiz de Mier, M. Victoria, et al.
Publicado: (2020)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

Serum Free Light Chain Only Myeloma with Cytoplasmic IgM
por: Ebana, Hideaki, et al.
Publicado: (2014)

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
por: Michallet, M, et al.
Publicado: (2018)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma
por: Bachmann, Ulrike, et al.
Publicado: (2008)

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma
por: Schieferdecker, Aneta, et al.
Publicado: (2020)

Evaluation of Correlation between Serum Free Light-Chain Assay and Bone Marrow Study in Multiple Myeloma Patients
por: Zamani, Fatemeh, et al.
Publicado: (2021)

Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma
por: Roose, James, et al.
Publicado: (2022)

Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
por: Cárdenas, Maria Cruz, et al.
Publicado: (2022)

Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study
por: De Novellis, Danilo, et al.
Publicado: (2022)

Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio
por: Zach, David, et al.
Publicado: (2021)

Triphenotypic multiple myeloma expressing kappa or lambda light chain or both
por: Liu, Yang, et al.
Publicado: (2013)

Multiple Myeloma–Associated Ig Light Chain Crystalline Cast Nephropathy
por: Matsumura, Hirotoshi, et al.
Publicado: (2020)

Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma
por: Olagunju, Abdulbaril, et al.
Publicado: (2022)

Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
por: Hegen, Harald, et al.
Publicado: (2023)

Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers
por: Donati, Gabriele, et al.
Publicado: (2016)

A method to obtain purified free light chain monomers and dimers from urine samples of patients with multiple myeloma
por: Caponi, Laura, et al.
Publicado: (2022)

All-trans-retinoic acid–induced pseudotumor cerebri in acute promyelocytic leukemia
por: Anoop, T. M., et al.
Publicado: (2014)

Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients
por: Espiño, M, et al.
Publicado: (2017)

Light chain proximal tubulopathy with cast nephropathy in a case of multiple myeloma
por: Gowda, K. K., et al.
Publicado: (2015)

Multiple myeloma-associated skin light chain amyloidosis: A case of misdiagnosis
por: XIAO, LI, et al.
Publicado: (2016)

Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges
por: Menè, Paolo, et al.
Publicado: (2022)

Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains
por: Sternke-Hoffmann, Rebecca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l581m98assv9t67t91nbvucfe0